ClinicalTrials.gg
CompletedNCT01431989Updated Jun 20, 2018Results posted

Amoxicillin Bioequivalence Study Brazil - Fast

A Phase 1 interventional study of Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL and Amoxil® 500mg/5mL powder for oral suspension in Infections, Bacterial, sponsored by GlaxoSmithKline. Completed at 1 site in Brazil. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-06-20.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2011, registered Sep 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Bacterial Infections by GlaxoSmithKline — 1 open to participants now, 1 under way, none of them phase 3. Bacterial Infections · GlaxoSmithKline.

Enrollment
17th of 33
28 · median 28
Started
2011
with 2 others
Phase 1
28 of 35
1 open now
Registered
12th of 35
by date

Among the 35 studies in Bacterial Infections by GlaxoSmithKline, this one is the 17th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2011, is one of 28 in phase 1, and was the 12th registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

1 of the 35 studies in Bacterial Infections by GlaxoSmithKline is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Bacterial Infections by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods. The volunteers received, in each period, the reference or the test formulation, according to the randomization list, under fasting conditions, in order to evaluate if the reference and test formulations are bioequivalent.

Read the detailed description

This study is prospective, open-label, randomized, crossover, single dose, with 02 treatments, 02 sequences and 02 periods. The objective is to confirm if two formulations of Amoxicillin trihydrate, in the form powder for oral suspension, are bioequivalent. The test product is Amoxicillin trihydrate - Clamoxyl 500mg/5mL (Glaxo Wellcome Production.) in the form powder for oral suspension and reference product is Amoxil ® 500mg/5mL (GlaxoSmithKline Mexico SA) in the form of powder for oral suspension. Twenty eight healthy volunteers, of both genders, were evaluated. The volunteers received, in each period, the reference or the test formulation, according to the randomization list, under fasting conditions. In each period blood samples are collected in the following times: 0.00 (prior to administration of medication); 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 (after administration of medication). The comparative bioavailability of the two formulations was evaluated based in statistical comparisons of relevant pharmacokinetic parameters, obtained from data of drug concentrations in blood.

03

Conditions studied

  • Infections, Bacterial

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 50 years
  • between 18,5 and 25,0, can vary up to 15% for the upper limit (18,5 and 28,75)
  • Good health conditions
  • Obtain signed

Exclusion criteria

Exclusion Criteria:

  • Results of laboratory tests outside the normal limits, unless they are considered clinically irrelevant
  • The volunteers who underwent surgery or who were hospitalized for any reason before the start of the study will be reviewed by the physician on admission in the study, observing a period of exclusion of 4 to 8 weeks
  • Positive test for , or in pre study evaluation
  • Known to the study drug or to compounds chemically related
  • Use of experimental drug or participation in any clinical study within 6 months prior to study initiation
  • Use of regular medication within 2 weeks prior to study initiation
  • History of alcohol or drugs abuse or intake of alcohol within 24 hours prior to the period of confinement
  • Consume of inductive drugs and/or enzymatic inhibitors (CYP450 - hepatic), that are toxic for the organism or presenting long half-life's elimination within 30 days prior to study initiation
  • Use of MAO and serotonin reuptake inhibitors within 2 weeks prior to study initiation
  • Volunteers with psychiatric or psychological illness unless they are considered clinically irrelevant by the investigator
  • History or presence of hepatic, renal or gastrointestinal illness or other condition that interferes on drug's absorption, distribution, excretion or metabolism
  • History of neurological, endocrine, pulmonary, hematologic, immune, brain, metabolic or cardiovascular illness
  • Hypo or hypertension of any etiologic that needs pharmacologic treatment
  • History or clinical case of myocardial infarction, angina and/or heart failure
  • The volunteer donated or lost 450 mL or more of blood within the 3 months prior to the study initiation
  • The volunteer has any condition that obstructs his/her participation in the study according the investigator's judgement
  • Smoking
  • Positive beta HCG exam for women
  • Breastfeeding women
  • Women making use of medication
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Active comparator
    Test formulation

    Test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 1; followed by 14-days washout period during which no medication was administered; followed by reference product: Amoxil® 500mg/5mL in Period 2.

    Drug: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL

  • Active comparator
    Reference formulation

    Reference product: Amoxil® 500mg/5mL powder for oral suspension in Period 1; followed by 14-days washout period during which no medication was administered; followed by test product: Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL in Period 2

    Drug: Amoxil® 500mg/5mL powder for oral suspension

Interventions

  • DrugAmoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL

    Drug page: Amoxicillin

    Test formulation

  • DrugAmoxil® 500mg/5mL powder for oral suspension

    Drug page: Amoxicillin

    Reference formulation

06

What researchers measure

Primary outcomes

  1. Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) to t (Last Measurable Concentration) (AUC0-t)

    The area under the plot of plasma concentration of drug against time (non-compartmental method), after drug administration, is defined as the area under the curve (AUC). AUC0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; mL, milliliter.

    Time frame: Collection points (hours [hrs]): 0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

  2. Maximum Observed Concentration of Drug Through Time (Cmax)

    Cmax is defined as the maximum or "peak" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed. Measurement is obtained directly from the plasma concentration curve of the drug (non-compartmental method).

    Time frame: Collection points (hrs): 0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

  3. Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) Extrapolated to Infinity (AUC0-inf)

    Measurement of AUC0-inf is obtained directly from the plasma concentration curve of drug against time (non-compartmental method). AUC0-inf is calculated from time 0 (prior to administration of medication) extrapolated to infinity, by using the formula AUC0-inf = AUC0-t + Clast/Kel, where Clast is the last measurable concentration, and Kel is the first-order rate constant associated with the terminal portion of the curve. AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.

    Time frame: Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods (Day 1 of Period 1[Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

  4. Time of Maximum Observed Concentration (Tmax)

    The time of maximum observed concentration (Tmax) is obtained directly from the plasma concentration curve of the drug by non-compartimental method. Tmax is of particular use in measuring bioavailability, by measuring the time at which the maximum concentration is achieved.

    Time frame: Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

  5. Percentage of AUC0-inf That is Due to Extrapolation From the Time of the Last Measurable Concentration to Infinity (AUC%Extrapolation)

    The percentage of AUC0-inf that is due to extrapolation from Tlast to infinity (AUC%Extrapolation) is calculated by using the formula AUC_%extrapolation = 100\*(AUC0-inf minus AUC0-t)/AUC0-inf. The function of this parameter is to provide information about what percentage of the theoretical curve (AUC0-inf) was possible to determine experimentally (AUC0-t) Therefore, on average, it is expected that the residual area (AUCextrapolation) is not greater than 20%.

    Time frame: Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

  6. Terminal Half-life (T1/2_Kel)

    T1/2_Kel is calculated by using the formula T1/2_Kel = Ln(2)/Kel.T1/2 is of particular use in measuring bioavailability, by measuring the elimination of the product.

    Time frame: Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

  7. First-order Rate Constant Associated With the Terminal Portion of the Curve (Kel)

    This parameter is estimated via linear regression of time versus log concentration. It allows for the obtainment of estimates of T1/2 (T1/2=ln(2)/Kel) considering the schedule and the detection limits defined.

    Time frame: Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])

07

Results

Posted Feb 7, 2012

Participant flow

Period 1
Participant flow — Period 1
MilestoneTest Product in Period 1: Reference Product in Period 2Reference Product in Period 1: Test Product in Period 2
Started1414
Completed1414
Not completed00
14-Day Washout Period
Participant flow — 14-Day Washout Period
MilestoneTest Product in Period 1: Reference Product in Period 2Reference Product in Period 1: Test Product in Period 2
Started1414
Completed1414
Not completed00
Period 2
Participant flow — Period 2
MilestoneTest Product in Period 1: Reference Product in Period 2Reference Product in Period 1: Test Product in Period 2
Started1414
Completed1414
Not completed00

Outcome measures

PrimaryArea Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) to t (Last Measurable Concentration) (AUC0-t)

The area under the plot of plasma concentration of drug against time (non-compartmental method), after drug administration, is defined as the area under the curve (AUC). AUC0-t is calculated from time 0 (prior to administration of medication) to time t (the time of the last quantifiable concentration). AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption. ng, nanograms; mL, milliliter.

Time frame:
Collection points (hours [hrs]): 0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · ng per hour per ml (ng*hr/mL)
Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) to t (Last Measurable Concentration) (AUC0-t)
ng per hour per ml (ng*hr/mL)Test ProductReference Product
Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) to t (Last Measurable Concentration) (AUC0-t)36431.460 ± 6806.79740426.451 ± 7279.259
Statistical analysis
  • Test Product vs Reference Product · ANOVA · p = 0.0000 · Ratio geometric mean t/r formulation: 90.03 · 90% CI 86.99 to 93.17The ratio between the geometric means of the test (T) and reference (R) formulations was calculated. Standard deviation intra subject was obtained.
PrimaryMaximum Observed Concentration of Drug Through Time (Cmax)

Cmax is defined as the maximum or "peak" concentration of a drug observed after its administration. Cmax is one of the parameters of particular use in estimating the bioavailability of drugs, by measuring the total amount of drug absorbed. Measurement is obtained directly from the plasma concentration curve of the drug (non-compartmental method).

Time frame:
Collection points (hrs): 0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · ng/mL
Maximum Observed Concentration of Drug Through Time (Cmax)
ng/mLTest ProductReference Product
Maximum Observed Concentration of Drug Through Time (Cmax)13615.929 ± 3886.86415176.107 ± 3144.162
Statistical analysis
  • Test Product vs Reference Product · ANOVA · p = 0.0018 · Ratio geometric mean t/r formulation: 87.93 · 90% CI 82.55 to 93.65The ratio between the geometric means of the test (T) and reference (R) formulations was calculated. Standard deviation intra subject was obtained.
PrimaryArea Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) Extrapolated to Infinity (AUC0-inf)

Measurement of AUC0-inf is obtained directly from the plasma concentration curve of drug against time (non-compartmental method). AUC0-inf is calculated from time 0 (prior to administration of medication) extrapolated to infinity, by using the formula AUC0-inf = AUC0-t + Clast/Kel, where Clast is the last measurable concentration, and Kel is the first-order rate constant associated with the terminal portion of the curve. AUC is of particular use in estimating the bioavailability of drugs, by measuring the extent of absorption.

Time frame:
Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods (Day 1 of Period 1[Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · ng*hr/mL
Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) Extrapolated to Infinity (AUC0-inf)
ng*hr/mLTest ProductReference Product
Area Under the Curve of Plasma Concentration of Drug From Time 0 (Zero) Extrapolated to Infinity (AUC0-inf)36908.392 ± 6875.78540977.755 ± 7372.809
Statistical analysis
  • Test Product vs Reference Product · ANOVA · p = 0.0000 · Ratio geometric means t/r formulation: 90.03 · 90% CI 86.96 to 93.12The ratio between the geometric means of the test (T) and reference (R) formulations was calculated. Standard deviation intra subject was obtained.
PrimaryTime of Maximum Observed Concentration (Tmax)

The time of maximum observed concentration (Tmax) is obtained directly from the plasma concentration curve of the drug by non-compartimental method. Tmax is of particular use in measuring bioavailability, by measuring the time at which the maximum concentration is achieved.

Time frame:
Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · hr
Time of Maximum Observed Concentration (Tmax)
hrTest ProductReference Product
Time of Maximum Observed Concentration (Tmax)1.304 ± 0.4681.482 ± 0.535
Statistical analysis
  • Test Product vs Reference Product · Wilcoxon (Mann-Whitney) · p = 0.3390 · Median difference (final values): 0.125 · 90% CI -0.125 to 0.375The non-parametric method included the following factors: Sequence, Formulation, Period, Formulation and Residual
PrimaryPercentage of AUC0-inf That is Due to Extrapolation From the Time of the Last Measurable Concentration to Infinity (AUC%Extrapolation)

The percentage of AUC0-inf that is due to extrapolation from Tlast to infinity (AUC%Extrapolation) is calculated by using the formula AUC_%extrapolation = 100\*(AUC0-inf minus AUC0-t)/AUC0-inf. The function of this parameter is to provide information about what percentage of the theoretical curve (AUC0-inf) was possible to determine experimentally (AUC0-t) Therefore, on average, it is expected that the residual area (AUCextrapolation) is not greater than 20%.

Time frame:
Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · percentage
Percentage of AUC0-inf That is Due to Extrapolation From the Time of the Last Measurable Concentration to Infinity (AUC%Extrapolation)
percentageTest ProductReference Product
Percentage of AUC0-inf That is Due to Extrapolation From the Time of the Last Measurable Concentration to Infinity (AUC%Extrapolation)1.303 ± 0.8141.353 ± 0.743
PrimaryTerminal Half-life (T1/2_Kel)

T1/2_Kel is calculated by using the formula T1/2_Kel = Ln(2)/Kel.T1/2 is of particular use in measuring bioavailability, by measuring the elimination of the product.

Time frame:
Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · hr
Terminal Half-life (T1/2_Kel)
hrTest ProductReference Product
Terminal Half-life (T1/2_Kel)1.085 ± 0.0711.137 ± 0.155
PrimaryFirst-order Rate Constant Associated With the Terminal Portion of the Curve (Kel)

This parameter is estimated via linear regression of time versus log concentration. It allows for the obtainment of estimates of T1/2 (T1/2=ln(2)/Kel) considering the schedule and the detection limits defined.

Time frame:
Collection points (hrs):0.00; 0.25; 0.50; 0.75; 1.00; 1.25; 1.50; 1.75; 2.00; 2.50; 3.00; 4.00; 5.00; 6.00; 8.00 evaluated in both periods: (Day 1 of Period 1 [Day 1 of study]; Day 1 of Period 2 [Day 15 of study])
Reported as:
Mean · 1/hr
First-order Rate Constant Associated With the Terminal Portion of the Curve (Kel)
1/hrTest ProductReference Product
First-order Rate Constant Associated With the Terminal Portion of the Curve (Kel)0.641 ± 0.0430.620 ± 0.079

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Test Product in Period 1 and Reference Product in Period 2—0/14 (0%)10/14 (71.4%)
Reference Product in Period 1 and Test Product in Period 2—0/14 (0%)4/14 (28.6%)
Most frequent other events
Most frequent other events
EventTest Product in Period 1 and Reference Product in Period 2Reference Product in Period 1 and Test Product in Period 2
Abnormal urine test resultsRenal and urinary disorders5/141/14
HeadacheGeneral disorders3/140/14
Head throbbingGeneral disorders0/141/14
Tension headacheGeneral disorders1/140/14
Urea increasedRenal and urinary disorders0/141/14
Triglycerides increasedBlood and lymphatic system disorders1/140/14
Glucose increasedBlood and lymphatic system disorders1/140/14
Bilirubin total increasedHepatobiliary disorders0/141/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants Receiving Both Test and Reference Products
Mean34.54 ± 7.38
Sex: Female, Male
Sex: Female, Male(Participants)Participants Receiving Both Test and Reference Products
Female14
Male14
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Participants Receiving Both Test and Reference Products
White10
Black4
Mulatto14
08

Study locations

1 site
  • GSK Investigational Site
    Goiania, Goiás, Brazil
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Jun 2011, 0 months.

Results were first posted in Feb 2012, 7 months after primary completion.

Of 52 industry-sponsored phase 1 interventional studies under Bacterial Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 0 months is below that.

Counting every sponsor, half of 67 studies reached it within 9 months; a quarter within 4 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2011
First posted
Sep 12, 2011
StartActual
May 27, 2011
Primary completionActual
Jun 11, 2011
CompletionActual
Jun 11, 2011
Results first posted
Feb 7, 2012
Last update
Jun 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01431989
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
May 27, 2011
Primary completion
Jun 11, 2011
Completion
Jun 11, 2011
Results posted
Feb 7, 2012
Last update
Jun 20, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amoxicillin

Start the discussion